GABY (GABLF) Corporate Presentation from NobleCon18Research, News and Market Data on GABYNobleCon 18 Complete Rebroadcast
|
Take it to the next level. It doesn’t cost a penny.
Join the Channelchek Investor Community. Your name, email, zip, and investor type is all it takes to open the door to research reports, favorites tracking, and virtual and in-person roadshows / conferences. Even exclusive investment opps.
‌
Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
‌
5/15/2024
Industrials
Release – Seanergy Maritime Reports Record Financial Results for the Quarter Ended March 31, 2024 and Declares Cash Dividends of $0.15 Per Share
Seanergy Maritime Holdings Corp. (“Seanergy” or the “Company”) (NASDAQ: SHIP), announced today its financial results for the first quarter ended March 31, 2024. The Company also declared a quarterly cash...
15 min read
‌
5/15/2024
Health
Release – PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious...
9 min read
‌
5/15/2024
Health
Release – ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial...
7 min read
‌
5/15/2024
Uncategorized
Release – Unicycive Therapeutics Presents Bioequivalence Data On Oxylanthanum Carbonate (OLC) At The National Kidney Foundation Spring Clinical Meeting
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company’s lead...
8 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.